Pharming Group N.V.

Share Issue/Capital Change • Sep 21, 2012

PHARMING UPDATES ON ONGOING CALL OF SECOND TRANCHE OF €10 MILLION EQUITY WORKING CAPITAL FACILITY

Leiden, The Netherlands, September 21, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announces that the investors have increased the ongoing call under the facility by 21,824,000 shares from 43,272,000 to 65,096,000.

Pharming also re-confirms that short selling is prohibited under this facility and also wishes to re-emphasize that both the timing and the amount of any tranche is determined by Pharming. Under the initial call of 16,000,000 shares made by the Company as announced on September 5, 2012, the individual investors have an option to purchase that is limited to up to 600% of these 16,000,000 shares during the 15 trading days of this call. Pharming previously announced on September 18, 2012 that the investors have made additional calls of 27,272,000 shares in total; this number has now been further increased by 21,824,000 shares.

Following the issue of the 21,824,000 shares, the number of outstanding shares increases from 851,089,129 shares to 872,913,129 shares.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RUCONEST ® is partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is undergoing Phase III clinical development. The product is also being evaluated for follow-on indications in the areas of transplantation and reperfusion injury. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. A feasibility study, using the validated transgenic rabbit platform, aimed at the development of recombinant Factor VIII for the treatment of Haemophilia A is underway with partner, Renova Life, Inc. Additional information is available on the Pharming website, www.pharming.com. To download the Pharming Group Investor Relations App, click here.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact

Sijmen de Vries, CEO: T: +31 (0)71 524 7400

FTI Consulting Julia Phillips/ John Dineen, T: +44 (0)207 269 7193

#